{"anticipatedPostingDate":"2010-06","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"Correlation of interleukin-15 production at day 0 with natural killer (NK) cells expansion","groups":[{"description":"Patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with 1 dose donor natural killer cells infusion, 4 doses rituximab, 6 doses aldesleukin and 5 doses fludarabine and 1 dose cyclosphosphamide.","id":"OG000","title":"Patients Treated With Natural Killer Cells"}],"paramType":"NUMBER","populationDescription":"Correlation of interleukin-15 with Natural Killer Cell expansion cannot be calculated because there was no Natural Killer Cell expansion.","reportingStatus":"POSTED","timeFrame":"Day 0","title":"Number of Patients With Interleukin-15 Production and NK Cell Expansion","type":"SECONDARY","unitOfMeasure":"Participants"}